

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Sunho Biologics, Inc.

盛禾生物控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2898)

FORMATION OF INDEPENDENT INVESTIGATION COMMITTEE AND CONTINUED SUSPENSION OF TRADING

This announcement is made by Sunho Biologics, Inc. (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 of the Rules (the “**Listing Rules**”) Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

References are made to the announcements (the “**Announcements**”) of the Company dated March 27, 2026, March 30, 2026, April 1, 2026, April 21, 2026, April 27, 2026 and May 3, 2026 in relation to the delay in publication of the 2025 Annual Results, postponement of Board Meeting, the suspension of trading of the Shares (the “**Shares**”) of the Company and the Resumption Guidance. Unless otherwise defined, capitalized terms used in this announcement shall have the same meanings as those defined in the Announcements.

ESTABLISHMENT OF INDEPENDENT INVESTIGATION COMMITTEE

The Board wishes to announce that at a meeting of the Board held on May 26, 2026, board resolutions have been passed for (i) the formation of an independent investigation committee (the “**Independent Investigation Committee**”) to undertake independent forensic investigation (the “**Independent Investigation**”) into the Matters; (ii) the appointment of Mr. CHAN Heung Wing Anthony, Ms. FENG Lan and Mr. SHI Luwen as the initial members of the Independent Investigation Committee, with Mr. CHAN Heung Wing Anthony being appointed as the chairman of the Independent Investigation Committee; and (iii) the authorization of the Independent Investigation Committee with all necessary powers, authorities, and rights to fulfill its duties, including but not limited to overseeing the Independent Investigation and related work, selecting suitable independent service providers to assist in carrying out the Independent Investigation, as well as approving the Company’s quarterly resumption update announcements.

The Company will make further announcement(s) in relation to the progress and results of the Independent Investigation as and when appropriate.

CONTINUED SUSPENSION OF TRADING

Trading in the shares of the Company on the Stock Exchange has been suspended with effect from 9:00 a.m. on April 1, 2026 and will continue to be suspended pending the publication of the 2025 Annual Results by the Company.

Shareholders and potential investors of the Company are advised to exercise due caution when dealing in the securities of the Company. When in doubt, shareholders and potential investors of the Company are advised to seek advice from professional or financial advisers.

By order of the Board
Sunho Biologics, Inc.
Mr. ZHANG Feng
Chairman and executive Director

Hong Kong, May 26, 2026

As at the date of this announcement, the executive Directors are Mr. ZHANG Feng and Ms. JIANG Xiaoling; the non-executive Director is Mr. FAN Rongkui; and the independent non-executive Directors are Mr. CHAN Heung Wing Anthony, Ms. FENG Lan and Mr. SHI Luwen.